ODT

On Demand Therapeutics (ODT) was a biotechnology company focused on developing a revolutionary intraocular drug delivery system for treating sight-threatening retinal diseases such as wet age-related macular degeneration (AMD) and diabetic retinopathy. The company's core technology, the ODTx platform, consisted of a multi-reservoir implantable device that could be non-invasively activated using a standard ophthalmic laser to release precise doses of medication. This approach aimed to replace the burden of frequent intravitreal injections with a single, long-term implant capable of storing and releasing multiple drugs over the course of a year. Founded in 2009 as a subsidiary of MicroCHIPS, the company leveraged micro-reservoir technology to provide on-demand, physician-controlled therapy directly to the back of the eye.